Recent research shows, the size of sponsors correlates with the size of service providers. Big Pharma relies on the large, full-service CROs if they are running a large clinical trial.
As the outsourcing world has always moved in cycles, today, there is a chance to change the situation. Mid-sized CROs can demonstrate to sponsors their experience and provide an evidence-based proof of expertise, needed to win a bigger project, e.g., multinational phase III trial.
Embracing RBM, a company’s smaller size can become an advantage.
Read more and download the White Paper
Leave A Comment
You must be logged in to post a comment.